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ABSTRACTSIntroduction: Patent Blue V dye is routinely used in the UK for Sentinel
Lymph node biopsy. However, it causes allergic reactions in (0.6-2.7%). The
NEWSTART and ALMANAC studies have reported 1% incidence. The ABS
guidelines 2009, recommends routine consenting for blue dye adminis-
tration and allergic reactions.
Materials and Methods: We looked into 41 cases of WLE/Mastectomy
with SLNB done over a 3 month period. All patients had 2ml of 2.5% PBV
injected subareolarly.
Results: 50% were consented for administration, and only 50% had allergic
responses mentioned. One patient had allergic reaction to blue dye man-
ifesting as intaoperative hypotension requiring ephedrine. There were no
delayed effects. Urticarial rashes, blue hives were seen in 3 patients but
were self-limiting. A similar audit done at a regional tertiary centre, the
consenting rates where 65% despite using pre-printed consent forms
because pre-printed consent forms were not used in all patients.
Conclusion: Patent Blue dye injection is not without risks and therefore
PBV administration and allergic responses to patent blue dye should
routinely be mentioned in consent forms. Using pre-printed forms can
improve the consenting rates, but it requires more awareness and persu-
ation among doctors.0563: THE USE OF CHEST X-RAYS AS A ROUTINE STAGING INVESTIGA-
TION FOR PATIENTS WITH INVASIVE BREAST CANCER e AN AUDIT OF
CURRENT PRACTICE
Hollie Sapsford 1, Nick Abbott 2. 1Raigmore Hospital, NHS Highland, Highland,
UK; 2Highland Breast Centre, NHS Highland, Highland, UK.
Aim: We investigated whether patients diagnosed with invasive breast
cancer in NHS Highland received a CXR in line with local preoperative
assessment guidelines.
Method: Data from all patients with invasive breast cancer diagnosed over
a 6 month period were retrieved from a prospectively maintained data-
base. Hospital notes and computer records identiﬁed if patients received a
pre-operative CXR.
Performing CXRs in 95% was deemed an acceptable audit standard.
Abnormal CXRs were identiﬁed and investigated in more detail.
Results: 111 Patients were diagnosed with invasive breast cancer.
Of the 98 patients who had surgery, 87 had a CXR (89%). Audit standard
failed.
68 CXRs were normal, although metastastic disease was subsequently
identiﬁed in 1 patient. 19 CXRs were abnormal, with 7 CXRs thought to be
due to a metastatic cause.
0 metastases were found in these patients on other imaging modalities.
Conclusions: Routine preoperative CXRs were not being performed in
accordance with local guidelines. Published national guidelines suggest
CXRs are not indicated in asymptomatic patients with invasive breast
cancer and clearly are not an effective tool in our population. Completing
the audit loop was thought unhelpful as this local data has changed
practice and helped suggest a more effective staging strategy.0565: CT OR NOT CT? HOW SHOULD WE LOOK FOR DISTANT METASTA-
SES IN INVASIVE BREAST CANCER IN NHS HIGHLAND?
Hollie Sapsford 1, Nick Abbott 2. 1Raigmore Hospital, NHS Highland, Highland,
UK; 2 The Highland Breast Centre, NHS Highland, Highland, UK.
Aim: Invasive breast cancer can metastasize to distant organs. SIGN(1)
Guidelines (84) suggest that no staging is required for T1-2 N0-1 tumours
in asymptomatic women. We aimed to identify an effective strategy for
staging investigations in NHS Highland.
Method: Data from all patients with invasive breast cancer diagnosed over
a 6 month period were retrieved from a prospectively maintained data-
base. Hospital notes and computer records identiﬁed staging in-
vestigations performed and the presence of conﬁrmed metastases.
Results: 111 patients were diagnosed with invasive breast cancer. 98 had
surgery. 5 were identiﬁed with asymptomatic metastases in the pre/peri-
operative period. 87 CXR were performed. 19 were abnormal. 0 metastases
identiﬁed 28 nucleotide bone scans. 9 abnormal. 2 metastases. 22 Liver USS.
4 abnormal. 0 metastases. 20 CT scans.13 abnormal. 3 metastases.
Conclusions: A low proportion of patients with metastases were identi-
ﬁed. CT chest/abdomen/pelvis is now used as the primary staging inves-
tigation for asymptomatic metastases in patients with preoperative
clinically bulky nodes, 4 nodes positive on post-operative histology and inpatients considered for reconstruction. Correlation with other screening
modalities is used if results are equivocal.
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Guideline. December 20050576: MALE BREAST CANCER AND THE ROLE OF GENETIC TESTING:
SHOULD WE INTRODUCE SIMBA (SCREENING IN MALE BREAST
CANCER)?
Simba. Mersey Research Group for Surgery (MeRGS), Mersey, UK.
Aims: To evaluate incidence of male breast cancer in Merseyside, assess
the proportion of BRCA2 carriers and explore if there is a beneﬁt of known
male gene carriers being offered screening.
Method:Retrospective cohort studyof5 centres inMerseyside reviewingmale
patients with breast cancer identiﬁed between 01/01/2000 and 31/10/2012.
Data collected on family history, BRCA gene testing, histology and treatment.
Results: Forty-ﬁve patients identiﬁed; median age 70years (range 37-93).
All presented with a breast lump. Fourty-one(91%) underwent mastec-
tomy; 36(80%) had grade 2/3 disease; 100% were ER+. Fifteen(33%) had
involved lymph-nodes and 10(22%) had lymphovascular invasion. All pa-
tients had anti-endocrine therapy, 6(13%) also underwent chemotherapy.
Six(13%) had family history of breast cancer, 5(11%) had BRCA testing, with
only one(2%) having a BRCA2mutation. The 5 year survial ratewas 62%(16/
26). 36%(4/11) of recorded deaths were related to breast cancer.
Conclusions: Incidence of male breast cancer in Merseyside appears lower
than national average. Findings suggest men have higher grade, ER+ tu-
mours and are likely to undergo mastectomy. Only a small proportion
underwent BRCA testing, raising the question should we be testing all male
breast cancers? Further work is ongoing evaluating BRCA2 rate in Mer-
seyside, in conjunction with Clinical Genetics.0596: ASIT-MAMMARY FOLD PRIZE WINNER: CYTOKERATIN-19 (CK19)
NEGATIVE BREAST CANCERS AND ONE-STEP NUCLEIC ACID AMPLIFICA-
TION (OSNA): MUCH ADO ABOUT NOTHING?
Dionysios-Dennis Remoundos 1, Meera Joshi 1, Farid Ahmed1, Yoon Chia 2,
Giles Cunnick 1,2. 1Department of Breast Surgery, Wycombe Hospital, High
Wycombe, UK; 2Department of Pathology, Wycombe Hospital, High Wycombe, UK.
Background: Sentinel Node Biopsy is standard practice for staging the axilla,
with OSNA more widely used in clinical practice. Nearly all breast cancers
express CK19, andOSNAdetects nodalmetastasis by quantifying the levels of
CK19 mRNA. Limited data exists on the true incidence of CK19-negative tu-
mours. Hence, we investigated the expression of CK19 in our practice.
Methods: All new breast cancer patients in a single centre between May
2010 and May 2012 were identiﬁed retrospectively. The tumour details,
including CK19 status, were retrieved from the pathology reports.
Results: 730 breast cancer patients were identiﬁed. 104 were excluded due
to incomplete data or lack of CK19 immunohistochemical (IHC) staining.
Details from 626 patients were analysed. 16 tumours were CK19-negative
(2.6%). The CK19 status was independent of the tumour histological and
hormone proﬁles. The median age of CK19-negative patients was older
than CK19-positive patients (76 vs 62 respectively).
Conclusions: This is one of the largest series looking at CK19-negative
tumours. As they are rare, routine testing prior to OSNA may not be
necessary. However, the exact correlation between CK19 expression by IHC
and the OSNA results remains uncertain. Studies investigating the pres-
ence or absence of CK19 mRNA may be more appropriate.0655: VTE PROPHYLAXIS FOR BREAST SURGERY; A PROSPECTIVE AUDIT
Miriam Thake, Sheila Shokuhi, Monika Kaushik. Department of Breast and
Oncoplastic Surgery, Glenﬁeld Hospital, University Hospitals of Leicester,
Leicester, UK.
Introduction: Each year approximately 25,000 people die from veno-
thrombolic events, 25 times the number that die from MRSA infection.
There is no consensus in the timing and dose of prophylactic LMWH in
patients undergoing breast surgery. The incidence of VTE in breast surgery
has been shown to be approximately 0.03%.
Aim: To compare the current practice of thromboprophylaxis for patients
undergoing breast surgery with the University Hospitals of Leicester (UHL)
protocol and NICE guidelines to standardise practice.
